Compare KSS & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | INVA |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1995 | 2000 |
| Metric | KSS | INVA |
|---|---|---|
| Price | $17.04 | $20.24 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 15 | 5 |
| Target Price | $15.31 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 3.8M | 589.5K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | 142.86 | ★ 816.67 |
| EPS | 1.18 | ★ 1.25 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | $0.21 | $12.65 |
| P/E Ratio | ★ $15.47 | $16.78 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $11.38 | $16.52 |
| 52 Week High | $25.22 | $25.15 |
| Indicator | KSS | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | N/A |
| Support Level | $18.23 | N/A |
| Resistance Level | $20.00 | N/A |
| Average True Range (ATR) | 0.74 | 0.00 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 65.35 | 0.00 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.